Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile
Ali et al., Journal of Pharmaceutical Research International, doi:10.9734/jpri/2020/v32i830468 (Dosing)
Ali et al., Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2020/v32i830468 (Dosing)
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Review of the mechanisms of action, pharmacokinetics and toxicity of HCQ, recommending use as early as possible with a loading dose in 3-4 divided doses to minimize toxicity, and daily maintenance divided into two doses, continued until remission.
Ali et al., 29 May 2021, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Pharmaceutical Research International 32(8): 29-43, 2020; Article no.JPRI.56916 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759) Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile Ahmed S. Ali1*, Mahran S. Abdel-Rahman2, Riyadh S. Almalikil3, Abir S. Mohamed4, Khalid A. Alfaifi5, Abdelbabgi El. Fadil6, Nagla A. El-Shitany7,8 and Huda M. Alkreathy1 1 Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, KSA. 2 Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt. 3 Department of Pharmacology, Faculty of Pharmacy, Umm Al-qura University, KSA. 4 Department of Internal Medicine, Faculty of Public Health and Tropical Medicine, Jazan University, KSA. 5 Department of Pharmacy, Medical Services Directorate, Taif, KSA. 6 Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, KSA. 7 Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, KSA. 8 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Authors’ contributions All authors actively participated in this reference research and major work. Author ASA designed the idea in cooperation with author MSAR. Author RSA early joined the team to organize communication between researchers. He prepares the introduction. Author ASA assumed full supervision of the research with the assistance of all colleagues author MSAR prepared the side effects of the drug he also reviewed all that colleagues author ASM reviewed all clinical issues related to COVID 19 patients and their management she described in details cardiac toxicity of HCQ. Author AEF revised all sections related to the novel virus description and epidemiology. Author KAA collected and reviewed the pharmacokinetics of HCQ and its integration with the efficacy and safety issues. Author NAES participated actively in explaining the mechanism of HCQ. She also provided the summary and conclusion. Author HMA provided huge effort to edit the review, in a professional way regarding all aspects, language, reference and connoting ideas etc. Article Information DOI: 10.9734/JPRI/2020/v32i830468 Editor(s): (1) Dr. Jongwha Chang, University of Texas, USA. Reviewers: (1) Victor B. Oti, Nasarawa State University, Nigeria. (2) Pichon Maxime, University Hospital of Poitiers, France. (3) Celso Ramos, National Institute of Public Health, Mexico. Complete Peer review History: http://www.sdiarticle4.com/review-history/56916 Review Article Received 23 April 2020 Accepted 12 May 2020 Published 29 May 2020 _____________________________________________________________________________________________________ *Corresponding author: E-mail: Profahmedali@gmail.com; ORCID: 0000-0002-3341-8177 Ali et al.; JPRI, 32(8): 29-43, 2020; Article no.JPRI.56916 ABSTRACT After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating patients with the new coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit